AstraZeneca Pharma India (NSE:ASTRAZEN) Net Income From Continuing Operations : ₹1,157 Mil (TTM As of Mar. 2025)

View and export this data going back to 2001. Start your Free Trial

What is AstraZeneca Pharma India Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. AstraZeneca Pharma India's net income from continuing operations for the three months ended in Mar. 2025 was ₹583 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Mar. 2025 was ₹1,157 Mil.

AstraZeneca Pharma India Net Income From Continuing Operations Historical Data

The historical data trend for AstraZeneca Pharma India's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AstraZeneca Pharma India Net Income From Continuing Operations Chart

AstraZeneca Pharma India Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Net Income From Continuing Operations

Get a 7-Day Free Trial

1,270.90

830.40

1,341.00

2,195.40

1,563.60

AstraZeneca Pharma India Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Net Income From Continuing Operations	Get a 7-Day Free Trial															394.80	-117.90	384.30	308.50	582.50

AstraZeneca Pharma India Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹1,157 Mil.

AstraZeneca Pharma India Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AstraZeneca Pharma India Ltd (NSE:ASTRAZEN) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

506820:India

Address

Outer Ring Road, Block N1, 12th Floor, Manyata Embassy Business Park, Rachenahalli, Bangalore, KA, IND, 560 045

Website

https://www.astrazeneca.com

AstraZeneca Pharma India Ltd is engaged in the manufacture, trading, and marketing of pharmaceutical products. Its only operating segment is Healthcare. The company generates revenue from the sale of products such as Tablets, Injectables, and Inhalation. Geographically, it derives a majority of its revenue from India. It focuses on areas such as Cardiovascular, Renal and Metabolism (CVRM), Oncology, Respiratory, Inflammation, Autoimmunity, Neuroscience Infection and Vaccines.

AstraZeneca Pharma India Headlines

No Headlines